University of Texas SPORE in Prostate Cancer

德克萨斯大学安德森癌症中心孢子治疗前列腺癌的战略计划是 将从了解肿瘤微环境的作用中获得的知识转化为临床 在疾病进展预测、治疗反应预测中的应用 前列腺癌患者的治疗进展。我们一直专注于相互关联的翻译 主题：靶向PDGF-R以提高化疗疗效；应用、验证和改进 白介素II受体靶向治疗前列腺癌骨转移 调节蛋白78作为监测前列腺癌新的配体受体对成像策略的初始靶点 癌症进展；阐明饮食和脂肪细胞在前列腺癌发生中的相对作用，并应用 临床知识；开发从骨中分离的成骨细胞调节因子MDA-BF1 前列腺癌骨转移患者骨髓标本作为预测和监测标志物的研究 前列腺癌在骨骼中的进展。我们的孢子召集了临床医生和基础科学家-包括 医学肿瘤学家、泌尿科医生、病理学家、放射肿瘤学家、发育生物学家、分子和 细胞生物学家、流行病学家、生物统计学家以及信息学和药物开发专家-实现 这些目标。该孢子汇集了基础科学家和临床科学家的主要互补优势。 参与前列腺癌研究的调查人员。这个孢子由五个科学项目和三个 支持核心。这些项目有很强的翻译重点：所有五个项目都研究人类前列腺 癌症，包括临床和基础研究人员、病理学家和生物统计学家参与概念、设计、 以及研究的执行情况。当整合后，我们的研究结果将导致患者管理 结合预测和预测标记物以及创新治疗方法的战略 其他的也在发展中。三个完善的核心，即行政、生物统计和生物信息学，以及 样本岩芯，由高级调查人员领导，支持这五个项目。核心资源提供了充分的 描述和临床注释人体组织和数据分析的专门知识。此外, 发展研究和职业发展计划将新的研究人员带入 孢子。前列腺癌中最初的M.D.安德森孢子领导了一项基于 在项目1中进行了实验观察。这次孢子间试验接近完成。此外，我们的 孢子调查员将继续参与制定统一的组织采购收集 和注解策略。这项前列腺癌孢子提案目标的实现将 为前列腺癌患者开发有效的治疗方法做出贡献。

The strategic plan of The University of Texas M. D. Anderson Cancer Center SPORE in Prostate Cancer is to translate the knowledge gained from understanding the roles of tumor microenvironments into clinical applications in the prognostication of disease progression, prediction of treatment response, and development of therapy for patients with prostate cancer. We have focused on interrelated translational themes: Targeting PDGF-R to enhance efficacy of chemotherapy; applying, validating, and refining an interleukin II receptor targeting treatment for patients with prostate cancer bone metastases; using glucose regulated protein 78 as an initial target for a new ligand receptor pair imaging strategy to monitor prostate cancer progression; elucidating relative roles of diet and adipocytes in prostate carcinogenesis, and applying the knowledge clinically; and developing MDA-BF1, an osteoblast regulatory factor isolated from bone marrow samples of patients with prostate cancer bone metastases, as a marker to predict and monitor prostate cancer progression in bone. Our SPORE has assembled clinicians and basic scientists-including medical oncologists, urologists, pathologists, radiation oncologists, developmental biologists, molecular and cell biologists, epidemiologists, biostatisticians, and experts in informatics and drug development-to achieve these goals. The SPORE brings together major complementary strengths of basic scientists and clinical investigators involved in prostate cancer research. This SPORE consists of five scientific Projects and three supporting Cores. The projects have a strongly translational focus: All five projects study human prostate cancer, and include clinical and basic investigators, pathologists, and biostatisticians in the concept, design, and execution of the studies. When integrated, the results of our studies will lead to a patient management strategy incorporating the prognostic and predictive markers and innovative treatment approaches we and others are developing. Three well-developed Cores, i.e., Administrative, Biostatistics and Bioinformatics, and Specimen cores, are led by senior investigators to support the five projects. The Core resources provide fully characterized and clinically annotated human tissues and data analysis expertise. In addition, Developmental Research and Career Development Programs have brought new investigators into the SPORE. The initial M. D. Anderson SPORE in Prostate Cancer leads an inter-SPORE trial based on experimental observations developed in Project 1. This inter-SPORE trial is near completion. In addition, our SPORE investigators will continue to participate in the development of uniform tissue procurement collection and annotation strategies. The achievement of the aims of this Prostate Cancer SPORE proposal will contribute to the development of effective treatments for patients with prostate cancer.